Skip to main content

Advertisement

SpringerLink
Log in

Alterations in Immune Function are Associated with Liver Enzyme Elevation in HIV and HCV Co-infection after Commencement of Combination Antiretroviral Therapy

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

The cause of liver enzyme elevation during combination antiretroviral therapy in people with human immunodeficiency virus and hepatitis C virus co-infection is unclear. We followed 12 subjects (five with alanine transaminase elevation) for 24 weeks after combination antiretroviral therapy commencement. Immune responses against hepatitis C virus, human immunodeficiency virus and other viruses were assessed by interferon-γ ELISpot. Plasma cytokines, chemokines and anti-hepatitis C virus antibody levels were measured. Those with liver enzyme elevation had higher ELISpot responses both against hepatitis C virus non-structural regions and other viral antigens, and their anti-hepatitis C virus antibody levels were consistently higher, suggesting that reconstitution of both hepatitis C virus-specific and non-hepatitis C virus-specific immune responses may be associated with liver transaminase elevation during combination antiretroviral therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. JAIDS. 2003;32:259–67.

    Article  PubMed  Google Scholar 

  2. Lo Re V, Kostman JR, Amorosa VK. Management complexities of HIV/HCV coinfection in the 21st century. Clin Liver Dis. 2008;12:587–609.

    Article  PubMed  Google Scholar 

  3. Rohrbach J, Robinson N, Harcourt G, Hammond E, Gaudieri S, Gorgievski M, et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut. 2010;59:1252–8.

    Article  PubMed  CAS  Google Scholar 

  4. Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis. 2002;186:1498–502.

    Article  PubMed  CAS  Google Scholar 

  5. Monforte Ade A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. JAIDS. 2001;28:114–23.

    PubMed  Google Scholar 

  6. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001. AIDS. 2003;17:2191–9.

    Article  PubMed  CAS  Google Scholar 

  7. Desombere I, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G. Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. J Clin Microbiol. 2005;43:2590–7.

    Article  PubMed  CAS  Google Scholar 

  8. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol. 2008;46:3880–91.

    Article  PubMed  CAS  Google Scholar 

  9. Cameron B, Bharadwaj M, Burrows J, Fazou C, Wakefield D, Hickie I, et al. Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load. J Infect Dis. 2006;193:664–71.

    Article  PubMed  CAS  Google Scholar 

  10. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary HCV infection. Cell Mol Life Sci. 2009;66:733–56.

    Article  PubMed  CAS  Google Scholar 

  11. Rea T, Russo J, Katon W, Ashley R, Buchwald D. Prospective study of the natural history of infectious mononucleosis caused by EBV. J Am Board Fam Pract. 2001;14:234–42.

    PubMed  CAS  Google Scholar 

  12. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol. 2001;75:11392–400.

    Article  PubMed  CAS  Google Scholar 

  13. Yunihastuti E, Lee S, Gani RA, Saraswati H, Sundaru H, Lesmana L, et al. Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART. Clin Immunol. 2011;139:32–9.

    Article  PubMed  CAS  Google Scholar 

  14. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38:S80–9.

    Article  PubMed  CAS  Google Scholar 

  15. Rallón NI, Soriano V, Restrepo C, García-Samaniego J, Labarga P, López M, et al. HCV-specific T cell Responses in HIV/HCV coinfected patients on HAART are comparable to those observed in HCV-monoinfected individuals. JAIDS. 2011;57:1–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Australian National Health and Medical Research Council [Program Grant No. 510488 “HIV and HCV vaccines and Immunopathogenesis”].

Author information

Author notes

  1. Carol R. Emerson

    Present address: Royal Victoria Hospital, Belfast Trust, Belfast, Northern Ireland

Authors and Affiliations

  1. Inflammation and Infection Research Centre, School of Medical Sciences, University of New South Wales, Sydney, NSW, 2052, Australia

    Barbara Anne Cameron & Andrew R. Lloyd

  2. Department of Infectious Diseases and Albion Street Centre, Prince of Wales Hospital, Randwick, NSW, 2031, Australia

    Carol R. Emerson & Jeffrey J. Post

  3. Prince of Wales Clinical School, University of New South Wales, Randwick, NSW, 2031, Australia

    Carol R. Emerson & Jeffrey J. Post

  4. AIDS Research Initiative, Darlinghurst, NSW, 2010, Australia

    Cassy Workman

  5. Brisbane Sexual Health and HIV Service, Brisbane, QLD, 4000, Australia

    Mark D. Kelly

Authors
  1. Barbara Anne Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol R. Emerson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cassy Workman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark D. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew R. Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeffrey J. Post
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara Anne Cameron.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cameron, B.A., Emerson, C.R., Workman, C. et al. Alterations in Immune Function are Associated with Liver Enzyme Elevation in HIV and HCV Co-infection after Commencement of Combination Antiretroviral Therapy. J Clin Immunol 31, 1079–1083 (2011). https://doi.org/10.1007/s10875-011-9587-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-011-9587-6

Keywords

Search

Navigation